About Lakewood-Amedex Biotherapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://lakewoodamedex.com
Frequently Asked Questions
What is the 52-week range for LABT?
The 52-week high is $98.2 and the 52-week low is $0.91.
What is the P/E ratio for LABT?
The P/E ratio data is currently unavailable.
What is the dividend yield for LABT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest LABT News
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.
Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections
Lakewood-Amedex Biotherapeutics CEO Kelvin Cooper joined Steve Darling from Proactive to announce a significant clinical milestone for the company, confirming that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of mildly infected diabetic foot ulcers. Cooper said the initiation of patient dosing marks an important step forward in the development of Nu-3, a topically applied antimicrobial gel that forms part of the company's proprietary Bisphosphocin® platform. The technology is designed to rapidly eliminate microbes directly at the site of infection while addressing one of the most pressing challenges in healthcare today—antimicrobial resistance (AMR). According to Cooper, Nu-3 has been developed as a fast-acting, broad-spectrum antimicrobial treatment that could provide a targeted alternative to conventional therapies by reducing microbial burden locally without relying on traditional systemic antibiotics. The Phase 2a study is designed to evaluate both the safety and efficacy of Nu-3 while helping determine the optimal dose for future clinical development. The multicenter, single-blinded, dose-finding trial is enrolling adult patients with either Type 1 or Type 2 diabetes who are suffering from mildly infected diabetic foot ulcers, a common and often difficult-to-treat complication of diabetes. Researchers will assess three different concentrations of the Nu-3 gel—2%, 5%, and 10%—to evaluate their ability to reduce infection and improve patient outcomes. The study will examine key endpoints related to safety, infection resolution, and reductions in microbial burden within the ulcer. Cooper noted that diabetic foot infections remain a significant healthcare challenge globally, often leading to prolonged treatment, hospitalization, and, in severe cases, amputation. The company believes Nu-3's localized antimicrobial approach may offer an important new option for patients while helping reduce reliance on conventional antibiotics. Topline results from the Phase 2a study are expected during the first quarter of 2027. If successful, Lakewood-Amedex plans to advance the program into a Phase 2b clinical trial. Cooper said the first patient dosing represents more than just the start of a clinical study—it is an important validation of the company's broader Bisphosphocin® antimicrobial platform and its potential role in addressing infectious diseases in an era of increasing antibiotic resistance. #proactiveinvestors #lakewood-amedex #nasdaq #labt #KelvinCooper #Biotech #AntimicrobialResistance #AMR #ClinicalTrials #Phase2 #DiabeticFootUlcers #InfectiousDiseases #DrugDevelopment #Biotechnology #Healthcare #MedicalResearch
Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported positive preclinical antimicrobial data for Nu-3 against recent clinical isolates from infected diabetic foot ulcers, ahead of Phase 2a topline results expected in the first quarter of 2027. Key Investor TakeawaysLakewood-Amedex Biotherapeutics (NASDAQ:LABT) said Nu-3 demonstrated consistent in vitro activity against recent diabetic foot ulcer clinical isolates, including drug-resistant pathogens.
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
These stocks are moving in today's pre-market session
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
By David Bautz, PhD NASDAQ: LABT READ THE FULL LABT RESEARCH REPORT Business Update First Patient Dosed in Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers On September 24, 2026, Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced the first patient dosed in the Phase 2a clinical trial of Nu-3 for the treatment of infected diabetic foot ulcers (iDFU). The trial will evaluate three
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated in a Phase 2a clinical trial as a topical treatment of mildly infected diabetic foot ulc
Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) on Thursday said it dosed the first patient in its Phase 2a clinical trial evaluating Nu-3 for mildly infected diabetic foot ulcers. The initiation of patient dosing represents a significant clinical milestone for Lakewood-Amedex Biotherapeutics as it accelerates the development of Nu-3. Lakewood-Amedex designed Nu-3 as a topically applied antimicrobial gel intended to rapidly eliminate harmful microbes directly at the site of infection. In addi
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic foot ulcers (iDFU).
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, has issued a Letter to Shareholders highlighting the Company's recent clinical, corporate and financial achievements and outlook as it advances Nu-3 into
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders
To our shareholders,The second quarter of 2026 represented a transformational period in the evolution of Lakewood-Amedex Biotherapeutics. We successfully transitioned to a Nasdaq-listed public company, significantly
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. 4,512,400 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,512,400 shares of common stock, par value $0.0001 per share, of Lakewood-Amedex
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial evaluating the safety and efficacy of its lead product candidate, Nu-3,
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-04-24 | Tucker Joseph Edward | +33,784 | - | - |